PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-4.87%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$7.52B
AUM Growth
+$7.52B
(-19%)
Cap. Flow
-$663M
Cap. Flow
% of AUM
-8.82%
Top 10 Holdings %
Top 10 Hldgs %
42.45%
Holding
173
New
32
Increased
18
Reduced
39
Closed
33
Top Buys
| 1 |
LABP
Landos Biopharma, Inc. Common Stock
LABP
|
$141M |
| 2 |
BridgeBio Pharma
BBIO
|
$64.7M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$55.4M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$49.5M |
| 5 |
Exact Sciences
EXAS
|
$46.6M |
Top Sells
| 1 |
Novavax
NVAX
|
$116M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$95.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
$93.1M |
| 4 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$90.4M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
$73.5M |
Sector Composition
| 1 | Healthcare | 84.38% |
| 2 | Financials | 0.28% |
| 3 | Industrials | 0.21% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
MacroGenics
MGNX
$121M
| $68.4M | 0.87% |
2,148,060
+887,000
| +70% | +$28.3M |
|
|
CERE
27
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $63.7M | 0.81% |
4,643,095
+99,033
| +2% | +$1.36M |
|
28
Athira Pharma
ATHA
$15.5M
| $63M | 0.8% |
3,425,916
+311,111
| +10% | +$5.72M |
|
29
Establishment Labs
ESTA
$1.11B
| $61.7M | 0.78% |
987,287
+290,654
| +42% | +$18.2M |
|
|
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
| $61.1M | 0.77% |
15,711,334
| – | – |
|
|
NARI
31
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $60.5M | 0.76% |
565,113
-103,387
| -15% | -$11.1M |
|
|
QTNT
32
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $59.6M | 0.75% |
16,200,818
| – | – |
|
|
MORF
33
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $59.4M | 0.75% |
938,140
+451,140
| +93% | +$28.5M |
|
|
ATNX
34
DELISTED
Athenex, Inc. Common Stock
ATNX
| $57.3M | 0.73% |
13,532,467
| – | – |
|
|
RXDX
35
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $55.4M | 0.7% |
+3,314,032
| New | +$55.4M |
|
36
RAPT Therapeutics
RAPT
$187M
| $55M | 0.7% |
2,477,481
+900,000
| +57% | +$20M |
|
37
Verrica Pharmaceuticals
VRCA
$49.4M
| $54.7M | 0.69% |
3,610,412
+200,000
| +6% | +$3.03M |
|
38
Crinetics Pharmaceuticals
CRNX
$3.26B
| $51.6M | 0.65% |
3,659,381
| – | – |
|
39
Veru
VERU
$48.5M
| $48M | 0.61% |
4,451,342
+1,201,342
| +37% | +$12.9M |
|
|
40
Exact Sciences
EXAS
$9.33B
| $46.6M | 0.59% |
+353,523
| New | +$46.6M |
|
41
VYNE Therapeutics
VYNE
$8.09M
| $46.4M | 0.59% |
6,773,954
-16,102,456
| -70% | +$7.22M |
|
42
Kodiak Sciences
KOD
$453M
| $44.1M | 0.56% |
389,008
-362,525
| -48% | -$41.1M |
|
43
Tarsus Pharmaceuticals
TARS
$2.44B
| $41.1M | 0.52% |
1,296,416
| – | – |
|
|
DBVT
44
DBV Technologies
DBVT
$249M
| $41M | 0.52% |
7,695,505
+1,100,000
| +17% | +$5.86M |
|
45
Allogene Therapeutics
ALLO
$249M
| $40.4M | 0.51% |
1,143,790
| – | – |
|
|
ARNA
46
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $39.9M | 0.5% |
575,007
| – | – |
|
47
Beam Therapeutics
BEAM
$1.9B
| $37.8M | 0.48% |
+537,635
| New | +$37.8M |
|
48
Lyra Therapeutics
LYRA
$11.8M
| $37.3M | 0.47% |
3,222,560
-1
| -0% | – |
|
49
Acadia Pharmaceuticals
ACAD
$4.34B
| $36.4M | 0.46% |
+1,410,305
| New | +$36.4M |
|
|
FMTX
50
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $35M | 0.44% |
1,250,000
| – | – |
|